Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chenodeoxycholic acid therapy for hypertriglyceridaemia in men.

M C Bateson, D Maclean, J R Evans

    British Journal of Clinical Pharmacology
    |March 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Identifying predictive markers for survival in malignant biliary obstruction following percutaneous transhepatic biliary drainage.

    Clinical radiology·2025
    Same author

    Machine Learning to Predict Prostate Artery Embolization Outcomes.

    Cardiovascular and interventional radiology·2024
    Same author

    A retrospective cohort study comparing a novel, spherical, resorbable particle against five established embolic agents for uterine fibroid embolisation.

    Clinical radiology·2021
    Same author

    Factors Predicting a Good Symptomatic Outcome After Prostate Artery Embolisation (PAE).

    Cardiovascular and interventional radiology·2018
    Same author

    Cortical Atrophy of the Brain in Infants associated with Failure to Thrive.

    Archives of disease in childhood·2010
    Same author

    The Treatment of Haemorrhoids.

    British medical journal·2010

    Chenodeoxycholic acid effectively lowers high triglyceride levels in patients with hypertriglyceridaemia when diet alone is insufficient. This bile acid treatment shows comparable efficacy to clofibrate for managing persistent hypertriglyceridaemia.

    Area of Science:

    • Metabolic Disorders
    • Pharmacology
    • Gastroenterology

    Background:

    • Hypertriglyceridaemia is a significant risk factor for cardiovascular disease.
    • Dietary modifications are the first line of treatment but may not fully control serum triglyceride levels.
    • Alternative or adjunct therapies are needed for persistent hypertriglyceridaemia.

    Purpose of the Study:

    • To evaluate the efficacy of chenodeoxycholic acid in managing hypertriglyceridaemia resistant to dietary control.
    • To compare the effectiveness of chenodeoxycholic acid with clofibrate in reducing serum triglyceride levels.

    Main Methods:

    • Ten patients with hypertriglyceridaemia on a low-carbohydrate diet were treated with chenodeoxycholic acid (750 mg/day) for 6 months.
    • Nine patients subsequently underwent a placebo-controlled crossover study with clofibrate (2 g/day).

    Related Experiment Videos

  • Serum triglyceride levels were monitored monthly throughout the study.

    • Main Results:

    • Dietary treatment alone reduced mean serum triglyceride levels by 36%.
    • Adding chenodeoxycholic acid resulted in a 47% reduction from initial values (P < 0.01).
    • Chenodeoxycholic acid therapy demonstrated a 47% reduction in triglyceride levels, comparable to clofibrate.

    Conclusions:

    • Chenodeoxycholic acid is an effective treatment for hypertriglyceridaemia not fully managed by diet.
    • Chenodeoxycholic acid may be as effective as clofibrate in lowering serum triglycerides.
    • Further research is warranted to confirm the long-term efficacy and safety of chenodeoxycholic acid for hypertriglyceridaemia.